SPIRE-1
The Evaluation of Bococizumab (PF-04950615) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)
- Stage
- klaar
- Medicine
- Bococizumab
- Population
- ASCVD
- Phase
- III
- First Patient In
- 15 February 2015
- Last Patient In
- 1 October 2016
- Last Patient Last Visit
- 23 December 2016
National Lead
dr. A. Mosterd
Cardioloog
Study Director
